+Compare
STXS
Stock ticker: ASE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
136.69M

STXS Stereotaxis Forecast, Technical & Fundamental Analysis

a designer of robotic cardiology instrument navigation systems

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for STXS with price predictions
07:00 PM EST Dec 03, 2023

STXS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for STXS turned positive on November 22, 2023. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on STXS as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

STXS moved above its 50-day moving average on November 24, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for STXS crossed bullishly above the 50-day moving average on November 29, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for STXS moved out of overbought territory on November 08, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

STXS broke above its upper Bollinger Band on November 03, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for STXS entered a downward trend on November 02, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.570) is normal, around the industry mean (25.181). P/E Ratio (0.000) is within average values for comparable stocks, (79.553). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.249). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (4.075) is also within normal values, averaging (44.232).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.4B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 4%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was -10%. LNDZF experienced the highest price growth at 347%, while GENE experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -42%. For the same stocks of the Industry, the average monthly volume growth was -62% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 69
Price Growth Rating: 60
SMR Rating: 84
Profit Risk Rating: 88
Seasonality Score: 19 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

STXS is expected to report earnings to fall 8.57% to -6 cents per share on March 12

Stereotaxis STXS Stock Earnings Reports
Q4'23
Est.
$-0.06
Q3'23
Missed
by $0.01
Q2'23
Est.
$-0.07
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.01
The last earnings report on November 09 showed earnings per share of -7 cents, missing the estimate of -5 cents. With 330.17K shares outstanding, the current market capitalization sits at 136.69M.
A.I. Advisor
published General Information

General Information

a designer of robotic cardiology instrument navigation systems

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
710 North Tucker Boulevard
Phone
+1 314 678-6100
Employees
130
Web
https://www.stereotaxis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UMLGX8.98N/A
N/A
Columbia Select Large Cap Growth Inst
LKBAX25.95N/A
N/A
LKCM Balanced
TSVAX17.33N/A
N/A
PGIM Quant Solutions Small-Cap Val A
CLQRX13.04N/A
N/A
Columbia Disciplined Core R
MSHOX12.83N/A
N/A
Morgan Stanley Inst Permanence C

STXS and

Correlation & Price change

A.I.dvisor tells us that STXS and ZIMV have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STXS and ZIMV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-0.56%
ZIMV - STXS
33%
Poorly correlated
+3.23%
RVTY - STXS
31%
Poorly correlated
+0.57%
CLPT - STXS
28%
Poorly correlated
+2.52%
QTRX - STXS
27%
Poorly correlated
-2.92%
CVRX - STXS
27%
Poorly correlated
+8.49%
More

Groups containing STXS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-0.56%
Medical Specialties
(undefined stocks)
21%
Poorly correlated
+0.47%
Medical Specialties
(undefined stocks)
21%
Poorly correlated
+0.47%
medical service
(undefined stocks)
21%
Poorly correlated
+1.24%
medical research
(undefined stocks)
20%
Poorly correlated
+1.16%
generic products
(undefined stocks)
18%
Poorly correlated
+2.20%
More